The incidence of neuroendocrine tumours (NETs) is on the rise in the UK. Patients with NETs need to be managed by a team of clinical specialties. There are a number of challenging gastrointestinal (GI) manifestations related to NETs that can occur in these patients, but a limited literature base exists to guide clinicians.
Whilst life expectancy can be several years for patients with NETs, the GI symptoms can have a significant impact on their quality of life. It is therefore imperative to be familiar with the common GI manifestations associated with NETs, so symptoms can be appropriately managed with an overall aim of restoring the patient’s quality of life.
- nutritional support
- gastrointestinal tumours
Statistics from Altmetric.com
Contributors SCC and TS developed the idea and layout of this review. VMS wrote the first draft of the manuscript. SCC, JJ, SS and TS subsequently revised and edited the final text and submitted manuscript.
Funding SS is funded by the Wellcome Trust Intermediate Fellowship (reference is 097162/Z/11/Z). Novartis provided a grant to pay for a research fellow.
Competing interests SCC is on the advisory board for Eli-Lilley and Covidien, and has received speaker's fees from Baxter and educational sponsorship for meetings by Calea, Abbvie, Shire and Covidien. Other authors have no completing interests to declare.
Provenance and peer review Not commissioned; internally peer reviewed.
Correction notice This paper has been amended since it was published Online First. Owing to a scripting error, some of the publisher names in the references were replaced with 'BMJ Publishing Group'. This only affected the full text version, not the PDF. We have since corrected these errors and the correct publishers have been inserted into the references.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.